Drug intelligence / Profile preview

SO-004

Development stage: Preclinical
Lead developer: Socium Therapeutics
Modality: Small Molecules

Overview

SO-004 is a small molecule immunotherapy efficacy improver currently in preclinical development by SOCIUM. It is a repositioned approved drug identified through SOCIUM's drug discovery platform to enhance the therapeutic effects of immune-oncology (IO) agents. The primary indication being explored is triple-negative breast cancer (TNBC), as well as other cancers where IO agents are indicated. SOCIUM is developing this asset in partnership with Nanjing Medical University. A derivative program, SO-004D, focuses on a new chemical entity (NCE) version of the compound based on the same mechanism of action.

Beyond the preview

Go deeper on SO-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SO-004.

Explore the full profile